Detection of bladder cancer using proteomic profiling of urine sediments

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Majewski, Tadeusz ^a   Spiess, Philippe E ^a,c   Bondaruk, Jolanta ^a   Black, Peter ^a,d   Clarke, Charlotte ^a,b   Benedict, William ^a   Dinney, Colin P ^a   Grossman, Herbert Barton ^a   Tang, Kuang S ^a   Czerniak, Bogdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; STUDENT T TEST; URINALYSIS; URINE SEDIMENT; UROTHELIUM;

ALPHA-DEFENSINS; CLUSTER ANALYSIS; HUMANS; MOLECULAR WEIGHT; NEOPLASM GRADING; NEOPLASM PROTEINS; PROTEOMICS; URINARY BLADDER NEOPLASMS;

EID: 84864536149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042452     Document Type: Article

References (50)

1. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, et al. (2004) Focus on bladder cancer. Cancer Cell 6: 111-116.
2. Spiess PE, Czerniak B, (2006) Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 130: 844-852.
3. Gazdar AF, Czerniak B, (2001) Filling the void: urinary markers for bladder cancer risk and diagnosis. J Natl Cancer Inst 93: 413-415.
4. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, et al. (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 63: 6971-6983.
5. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, et al. (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65: 323-332.
6. Zhu W, Wang X, Ma Y, Rao M, Glimm J, et al. (2003) Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 100: 14666-14671.
7. Gaston KE, Grossman HB, (2010) Proteomic assays for the detection of urothelial cancer. Methods Mol Biol 641: 303-323.
8. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
9. Petricoin EF, Liotta LA, (2003) Clinical applications of proteomics. J Nutr 133: 2476S-2484S.
10. Baggerly KA, Edmonson SR, Morris JS, Coombes KR, (2004) High-resolution serum proteomic patterns for ovarian cancer detection. Endocr Relat Cancer 11: 583-584; author reply 585-587.
11. Baggerly KA, Morris JS, Coombes KR, (2004) Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20: 777-785.
12. Baggerly KA, Morris JS, Edmonson SR, Coombes KR, (2005) Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97: 307-309.
13. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA, (2005) Serum proteomics profiling-a young technology begins to mature. Nat Biotechnol 23: 291-292.
14. FK M, IA S (1999) Histological typing of urinary bladder tumors. Histological Typing of urinary bladder tumors. New York Berlin: Springer.
15. Sobin OH, Wittekind C (1999) TNM classification of malignant tumors. International Union Against Cancer (UICC). New York: John Willey & Sons.
16. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, et al. (2005) Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Laboratory Investigation 85: 532-549.
17. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, et al. (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94: 1320-1329.
18. Thulasiraman V, McCutchen-Maloney SL, Motin VL, Garcia E, (2001) Detection and identification of virulence factors in yersinia pestis using SELDI ProteinChip System. Biotechniques 30: 428-432.
19. Vorderwulbecke S, Cleverley S, Weinberger SR, Wiesner A, (2005) Protein Quantification by the SELDI-TOF-MS-based ProteinChip System. Nature Methods 2: 393-395.
20. Coombes KR, Tsavachidis S, Morris JS, Baggerly KA, Hung MC, et al. (2005) Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics 5: 4107-4117.
21. Morris JS, Coombes KR, Koomen J, Baggerly KA, Kobayashi R, (2005) Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics 21: 1764-1775.
22. Zhang L, Yu W, He T, Yu J, Caffrey RE, et al. (2002) Contribution of human α-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298: 995-1000.
23. Holterman DA, Diaz JI, Blackmore PF, Davis JW, Shellhammer PF, et al. (2006) Overexpression of α-defensin is associated with bladder cancer invasiveness. Urologic Oncology: Seminary and Original Investigations. 24: 97-108.
24. Muller CA, Markovic-Lipkovski J, Klatt T, Gamper J, Schwarz G, et al. (2002) Human α-defensins HNPs-1,-2, and-3 in renal cell carcinoma: invludences on tumor cell proliferation. Am J Pathol 160: 1311-1324.
25. Abbod MF, Catto JWF, Chen M. Artificial Intelligence Techniques for the Prediction of Bladder Cancer Progression; 2005 April 27-29, 2005; Bruges, Belgium. 109-114.
26. Catto JW, Linkens DA, Abbod MF, Chen M, Burton JL, et al. (2003) Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. Clin Cancer Res 9: 4172-4177.
27. Liu W, Guan M, Wu D, (2005) Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. European Urology 47: 456-462.
28. Pisitkun T, Johnstone R, Knepper MA, (2006) Discovery of urinary biomarkers. Mol Cell Proteomics 5: 1760-1771.
29. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, et al. (2002) Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48: 1835-1843.
30. Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, et al. (2005) ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol47: 885-893; discussion 893-884.
31. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, et al. (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158: 1491-1502.
32. Schwamborn K, Gaisa NT, Henkel C, (2010) Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers. Expert Rev Proteomics 7: 897-906.
33. Cho WC, Cheng CH, (2007) Oncoproteomics. 4: 401-410.
34. Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, et al. (2009) Genoproteomic mining of urothelial cancer suggests γ-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. Am J Pathol 175: 1824-1830.
35. Van QN, Veenstra TD, Issaq HJ, (2011) Metabolic profiling for the detection of bladder cancer. Curr Urol Rep 12: 34-40.
36. Cho WS, (2007) Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 6: 1-13.
37. Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, et al. (2011) Reproducibility of SELDI Spectra Across Time and Laboratories. Cancer Inform 10: 45-64.
38. Kehinde EO, Al-Mulla F, Kapila K, Anim JT, (2011) Comparison of the sensitivity and specificty of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer. J Urol Nephrol 45: 113-121.
39. Sanchez-Carbayo M, (2004) Recent advances in bladder cancer diagnostics. Clin Biochem 37: 562-571.
40. Goodison S, Rosser CJ, Urquidi V, (2009) Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteomics 6: 507-514.
41. Huang Z, Lin L, Gao Y, Chen Yongjing C, Yan X, et al. (2011) Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol Cell Proteomics 10: M111.007922, Epub 2011.
42. Lu M, Faull KF, Whitelegge JP, He J, Shen D, et al. (2007) Proteomics and mass spectrometry for cancer biomarker discovery. Biomarker Insights 2: 347-360.
43. Roesch-Ely M, Nees M, Karsai S, Ruess A, Bogumil R, et al. (2007) Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 26: 54-64.
44. Khwaja FW, Nolen JDL, Mendrinos SE, Lewis MM, Olson JJ, et al. (2006) Proteomic analysis of cerebrospinal fluid discriminates maligant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6: 6277-6287.
45. Pan S, Chen R, Stevens T, Bronner MP, May D, (2011) Proteomics portrait of archival lesions of chronic pancreatitis. Plos One 6: 1-12.
46. Conrad DH, Goyette J, Thomas PS, (2007) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23: 78-84.
47. Coffelt SB, Scandurro AB, (2008) Tumors sound the alarmin(s). Cancer Res 68: 6482-6485.
48. Droin N, Hendra JB, Ducoroy P, Solary E, (2009) Human defensins as cancer biomarkers and antitumour molecules. J Proteomics 72: 918-927.
49. Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Winther B, et al. (2005) Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 5: 1-10.
50. Sun CQ, Arnold R, Fernandez-Golarz C, Parrish AB, Almekinder T, et al. (2006) Human β-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res 66: 8542-8549.